A retrospective study to evaluate efficacy of switching to intravitreal aflibercept in patients with macular oedema secondary to central retinal vein occlusion who received prior treatment with intravitreal ranibizumab or bevacizumab therapy

Trial Profile

A retrospective study to evaluate efficacy of switching to intravitreal aflibercept in patients with macular oedema secondary to central retinal vein occlusion who received prior treatment with intravitreal ranibizumab or bevacizumab therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top